Back to News
Market Impact: 0.15
Rakovina Adds Yale Scientist Bindra To Advisory Board As DDR Pipeline Advances
Source: Nasdaq
Healthcare & BiotechArtificial IntelligenceManagement & Governance
Rakovina Therapeutics appointed Dr. Ranjit Bindra, Scientific Director of the Yale Brain Tumor Center, to its Scientific Advisory Board. The appointment supports the company's advancement of its AI-driven oncology pipeline, though no clinical, financial, or development milestone was disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
RKV0.45
More News
- Australia’s central bank chief warns inflation risks materialising
- This AI-picked stock jumps 18% on Amazon’s $8 billion power deal
- Asian stocks rise as oil retreat eases inflation fears, BOJ in focus
- California AG Bonta on Paramount-Warner Bros., Meta and AI
- A breakout in the 10-year Treasury yield could hold back stocks if it reaches this level
- Fed rate decision and Warsh comments roiled markets. Where to find opportunities